ACI - Life Sciences Patents
January 13-14, 2015
New York, NY
Site: DoubleTree Suites by Hilton Times Square
Decisions like Myriad and Prometheus have left specific types of patents subject to an onslaught of challenges, while decisions like Gilead and developments in PTO procedures have left entire patent portfolios hanging in the balance. Attend this event and walk away with tailored patent strategies you can immediately incorporate into your practice regarding §101 patentability, double patenting type obviousness, and written description and indefiniteness challenges.
Our accomplished faculty — a veritable “Who’s Who” of the life sciences patent bar — have united to provide comprehensive updates and strategic solutions to protect life sciences patents.
In-house representatives from Merck, Novartis, Biogen, Roche, and many more will share the methods that have worked for them in recent battles, and provide specific advice to protect your patent portfolio cost-effectively. Furthermore, this year’s conference features a new session in which former leaders from the USPTO and the Federal Circuit – including David Kappos and The Honorable Paul Michel – discuss patentability and the role of both agencies in the future of continued investment in life sciences R&D.
Terry Rea is speaking on the topic "Lessons Learned From the First IPRs and PGRs: Best Practices for Offensive and Defensive Use of AIA Procedures in the Life Sciences Space
Crowell & Moring Participant(s):
For more information, please visit these areas: